Clinical Trials Logo

Retinal Vein Occlusion clinical trials

View clinical trials related to Retinal Vein Occlusion.

Filter by:

NCT ID: NCT01580020 Completed - Clinical trials for Retinal Vein Occlusion

Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO

Start date: May 2012
Phase: Phase 4
Study type: Interventional

The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the initial 6-month treatment in the respective core studies CRFB002EDE17 and CRFB002EDE18.

NCT ID: NCT01573572 Completed - Clinical trials for Diabetic Macular Edema

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Start date: April 22, 2010
Phase: Phase 4
Study type: Interventional

This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.

NCT ID: NCT01571557 Completed - Macular Edema Clinical Trials

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

Start date: April 30, 2012
Phase:
Study type: Observational

This study will evaluate the relationship between time since onset of macular oedema symptoms and the achievement of vision gain in patients prescribed OZURDEX®. All care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and local standard of medical care.

NCT ID: NCT01568021 Completed - Macular Edema Clinical Trials

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Start date: October 2011
Phase: N/A
Study type: Observational

This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.

NCT ID: NCT01566526 Completed - Clinical trials for Retinal Vein Occlusion

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Start date: March 2012
Phase: N/A
Study type: Observational

The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.

NCT ID: NCT01539577 Completed - Macular Edema Clinical Trials

A Long-Term Safety Study of OZURDEX® in Clinical Practice

Start date: March 2012
Phase: N/A
Study type: Observational

This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or patients with non-infectious posterior segment uveitis in real-world clinical practice.

NCT ID: NCT01535261 Completed - Macular Edema Clinical Trials

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

CRYSTAL
Start date: February 2012
Phase: Phase 3
Study type: Interventional

The present study will provide additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion (CRVO). Spectral domain high-definition optical coherence tomography (OCT) images will be analyzed to gain insights into predictive factors for disease progression and the possibility of reduced monitoring will be assessed in Year 2. The results of this open-label study will provide long-term safety and efficacy data to further guide recommendations on the use of ranibizumab in this indication.

NCT ID: NCT01531842 Unknown status - Clinical trials for Age-related Macular Degeneration

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

Start date: August 2011
Phase: N/A
Study type: Interventional

This is a research study to evaluate the effects of repeated intravitreal injections on bacteria around the eye.

NCT ID: NCT01521559 Completed - Clinical trials for Branch Retinal Vein Occlusion

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

VIBRANT
Start date: April 2012
Phase: Phase 3
Study type: Interventional

This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.

NCT ID: NCT01512901 Completed - Clinical trials for Macular Edema Following Branch Retinal Vein Occlusion

Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for macular edema following branch retinal vein occlusion